Brief: Shanghai Fosun Pharmaceutical's Unit To Buy Stake In Henlius Biotech
21/04/2025 09:18
April 21 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS: SAYS UNIT PLANS TO BUY AROUND 3.87% STAKE IN SHANGHAI HENLIUS BIOTECH INC FOR HK$ 517.4 MILLION ($66.67 million) Source text Further company coverage: 600196.SS ($1 = 7.7608 Hong Kong dollars) (Reporting by Beijing Newsroom) ((yukun.zhang@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln